Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Risk of Acute Kidney Injury Following IV Iodinated Contrast Media Exposure: 2023 Update, From the AJR Special Series on Contrast Media
McDonald, Robert J. , McDonald, Jennifer S.

Mayo Clinic

American Journal of Roentgenology | October 4, 2023 | Volume: 223 | Issue: 1 | Pages: No page available

10.2214/ajr.23.30037 | PMID 37791729 Get It

Significant Reduction in the Diagnosis of Barrett's Esophagus and Related Dysplasia During the COVID-19 Pandemic
Pokala, Sridevi K. , Williams, J. Lucas, Holub, Jennifer L., Calderwood, Audrey H. , Iyer, Prasad G. , Shaheen, Nicholas J. , Wani, Sachin , Dominitz, Jason A.

Mayo Clinic

American Journal of Gastroenterology | October 2, 2023 | Volume: 119 | Issue: 2 | Pages: 251-261

10.14309/ajg.0000000000002527 | PMID 37782262 Get It

INTRODUCTION: The coronavirus disease 19 (COVID-19) pandemic disrupted endoscopy practices, creating unprecedented decreases in cancer screening and surveillance services. We aimed to assess the impact of the pandemic on the proportion of patients diagnosed with Barrett's esophagus (BE) and BE-related dysplasia and adherence to established quality indicators. METHODS: Data from all esophagogastroduodenoscopies in the GI Quality Improvement Consortium, a national repository of matched endoscopy and pathology data, were analyzed from January 2018 to December 2022. Four cohorts were created based on procedure date and COVID-19 data: pre-pandemic (January 2018 to February 2020), pandemic-phase I (March 2020 to July 2020), pandemic-phase II (August 2020 to May 2021), and pandemic-phase III (June 2021 to December 2022). Observed and expected number of BE and BE-related dysplasia cases per month and adherence to the Seattle biopsy protocol and recommended surveillance intervals for nondysplastic BE (NDBE) were evaluated. RESULTS: Among 2,446,857 esophagogastroduodenoscopies performed during the study period, 104,124 (4.3%) had pathology-confirmed BE. The histologic distribution was 87.4% NDBE, 1.8% low-grade dysplasia, 2.4% indefinite for dysplasia, and 1.4% high-grade dysplasia. The number of monthly BE (−47.9% pandemic-phase I, −21.5% pandemic-phase II, and −19.0% pandemic-phase III) and BE-related dysplasia (high-grade dysplasia: 41.2%, −27.7%, and −19.0%; low-grade dysplasia: 49.1%, −35.3%, and −26.5%; any dysplasia: 46.7%, −32.3%, and −27.9%) diagnoses were significantly reduced during the pandemic phases compared with pre-pandemic data. Adherence rates to the Seattle protocol and recommended surveillance intervals for NDBE did not decline during the pandemic. DISCUSSION: There was a significant decline in the number of BE and BE-related dysplasia diagnoses during the COVID-19 pandemic, with an approximately 50% reduction in the number of cases of dysplasia diagnosed in the early pandemic. The absence of a compensatory increase in diagnoses in the pandemic-phase II and III periods may result in deleterious downstream effects on esophageal adenocarcinoma morbidity and mortality.
Surgical resection of recurrent intramedullary subependymoma of the cervical spinal cord
Perez, Jennifer L. , Potes, Maria Astudillo , Rotter, Juliana , Everson, Megan C., Astudillo Potes, Maria D, Raghunathan, Aditya , Clarke, Michelle J.

Mayo Clinic

Neurosurgical Focus: Video | October 1, 2023 | Volume: 9 | Issue: 2 | Pages: V7

10.3171/2023.7.focvid2394 | PMID 37854659 Get It

Spinal subependymomas (SE) are rare, often indolent benign tumors presenting most frequently as intramedullary tumors in the cervical spine or cervicothoracic junction. When symptomatic, patients often present with years of sensory changes, weakness, paresthesias, or bowel and bladder dysfunction. Preoperatively, SE are difficult to distinguish radiographically from ependymomas or astrocytomas; however, it is important to make the distinction intraoperatively as complete resection can be curative. Here the authors present a rare case of recurrent, symptomatic cervical subependymoma which underwent gross-total resection and discussion of management strategies and outcomes of all SE at their institution.
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
Lee, Jae , Knievel, Kerry, McVige, Jennifer , Wang, Weiying , Gillard, Patrick, Shah, Darshini, Blumenfeld, Andrew , Schwedt, Todd J. , Wu, Zheng

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 10 | Pages: 1119-1128

10.18553/jmcp.2023.29.10.1119 | PMID 37776119 Get It

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Rivero, Jaydira Del , Perez, Kimberly , Kennedy, Erin B. , Mittra, Erik , Vijayvergia, Namrata , Arshad, Junaid , Basu, Sandip , Chauhan, Aman , Dasari, Arvind , Bellizzi, Andrew M. , Gangi, Alexandra , Grady, Erin , Ivanidze, Jana , Lewis, Mark A. , Mailman, Josh , Raj, Nitya , White, Sarah B. , Chan, Jennifer A. , Kunz, Pamela L. , Singh, Simron , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Raj, Nitya , Soares, Heloisa P , Soulen, Michael C , Kunz, Pamela L , Singh, Simron , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Bergsland, Emily K , Chauhan, Aman , Bellizzi, Andrew M , Vijayvergia, Namrata , Arshad, Junaid , Howe, James R. , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 32 | Pages: 5049-5067

10.1200/jco.23.01529 | PMID 37774329 Get It

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome
Satoh, Ryota , Weigand, Stephen D. , Pham, Nha Trang Thu, Ali, Farwa , Arani, Arvin , Jack, Clifford R. , Whitwell, Jennifer L. , Josephs, Keith A. , Josephs, Keith A , Jack, Clifford R , Arani, Arvin , Satoh, Ryota , Senjem, Matthew L.

Mayo Clinic

Movement Disorders | September 29, 2023 | Volume: 38 | Issue: 12 | Pages: 2282-2290

10.1002/mds.29613 | PMID 37772771 Get It

AbstractBackgroundPrevious studies have shown that magnetic susceptibility is increased in several subcortical regions in progressive supranuclear palsy (PSP). However, it is still unclear how subcortical and cortical susceptibilities vary across different PSP variants, Parkinson's disease (PD), and corticobasal syndrome (CBS).ObjectiveThis study aims to clarify the susceptibility profiles in the subcortical and cortical regions in different PSP variants, PD, and CBS.MethodsSixty‐four patients, 20 PSP‐Richardson syndrome (PSP‐RS), 9 PSP‐parkinsonism (PSP‐P), 7 PSP‐progressive gait freezing, 4 PSP‐postural instability, 11 PD, and 13 CBS, and 20 cognitively normal control subjects underwent a 3‐Tesla magnetic resonance imaging scan to reconstruct quantitative susceptibility maps. Region‐of‐interest analysis was performed to obtain susceptibility in several subcortical and cortical regions. Bayesian linear mixed effect models were used to estimate susceptibility within group and differences between groups.ResultsIn the subcortical regions, patients with PSP‐RS and PSP‐P showed greater susceptibility than control subjects in the pallidum, substantia nigra, red nucleus, and cerebellar dentate (P < 0.05). Patients with PSP‐RS also showed greater susceptibility than patients with PSP‐progressive gait freezing, PD, and CBS in the red nucleus and cerebellar dentate, and patients with PSP‐P showed greater susceptibility than PD in the red nucleus. Patients with PSP‐postural instability and CBS showed greater susceptibility than control subjects in the pallidum and substantia nigra. No significant differences were observed in any cortical region.ConclusionsThe PSP variants and CBS had different patterns of magnetic susceptibility in the subcortical regions. The findings will contribute to our understanding about iron profiles and pathophysiology of PSP and may provide a potential biomarker to differentiate PSP variants, PD, and CBS. © 2023 International Parkinson and Movement Disorder Society.
Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria
Fain, Cori E. , Zheng, Jiaying , Jin, Fang, Ayasoufi, Katayoun , Wu, Yue , Lilley, Meredith T. , Dropik, Abigail R. , Rodriguez, Robert C , Aibaidula, Abudumijiti, Tritz, Zachariah P. , Bouchal, Samantha M. , Pewe, Lecia L. , Urban, Stina L. , Chen, Yin, Chang, Su-Youne , Hansen, Michael J. , Kachergus, Jennifer M., Shi, Ji , Thompson, E. Aubrey , Jensen, Hadley E, Harty, John T. , Wu, Long‐Jun , Johnson, Aaron J. , Wolf, Delaney M. , Tritz, Zachariah P , Parney, Ian F , Wu, Long-Jun , Johnson, Aaron J. , Ayasoufi, Katayoun , Lilley, Meredith T , Dropik, Abigail R , Zheng, Jiaying , Bouchal, Samantha M , Parney, Ian F. , Sun, Jie

Mayo Clinic

Brain | September 28, 2023 | Volume: 147 | Issue: 2 | Pages: 566-589

10.1093/brain/awad319 | PMID 37776513 Get It

Abstract Cerebral malaria is the deadliest complication that can arise from Plasmodium infection. CD8 T-cell engagement of brain vasculature is a putative mechanism of neuropathology in cerebral malaria. To define contributions of brain endothelial cell major histocompatibility complex (MHC) class I antigen-presentation to CD8 T cells in establishing cerebral malaria pathology, we developed novel H-2Kb LoxP and H-2Db LoxP mice crossed with Cdh5-Cre mice to achieve targeted deletion of discrete class I molecules, specifically from brain endothelium. This strategy allowed us to avoid off-target effects on iron homeostasis and class I-like molecules, which are known to perturb Plasmodium infection. This is the first endothelial-specific ablation of individual class-I molecules enabling us to interrogate these molecular interactions. In these studies, we interrogated human and mouse transcriptomics data to compare antigen presentation capacity during cerebral malaria. Using the Plasmodium berghei ANKA model of experimental cerebral malaria (ECM), we observed that H-2Kb and H-2Db class I molecules regulate distinct patterns of disease onset, CD8 T-cell infiltration, targeted cell death and regional blood–brain barrier disruption. Strikingly, ablation of either molecule from brain endothelial cells resulted in reduced CD8 T-cell activation, attenuated T-cell interaction with brain vasculature, lessened targeted cell death, preserved blood–brain barrier integrity and prevention of ECM and the death of the animal. We were able to show that these events were brain-specific through the use of parabiosis and created the novel technique of dual small animal MRI to simultaneously scan conjoined parabionts during infection. These data demonstrate that interactions of CD8 T cells with discrete MHC class I molecules on brain endothelium differentially regulate development of ECM neuropathology. Therefore, targeting MHC class I interactions therapeutically may hold potential for treatment of cases of severe malaria.
A-373 Comparison of the CoaguChek ® and Coag-Sense ® PT2 Meter Point of Care INR Devices
Schumann, Thomas L. , Karon, Barry L., O’Connor, Clare , Jennifer, L, Blanco, J, Hartman, Lisa L.R., Uy, J. , Myhre, Nikki K., GAYLE, DAVID D., Hartung, K, David, H., Santrach, Paula J., O'Connor, C, Jennifer, L, Kramer, A, Hartung, K, David, H, McBane, Robert D.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.329 Get It

Abstract Background Warfarin monitoring may be done at the point-of-care (POC) at home, in a clinic environment, or be performed using plasma specimens in a central laboratory. With a goal of standardizing International Normalization Ratio (INR) measurements and improving data integrity by enabling electronic transmission of results from any location, we evaluated two POC INR devices against an internal plasma INR reference method. Methods We conducted a multicenter study to test the accuracy of two commercially available point of care devices: Coag-Sense PT2 Meter (Coagusense, Inc., Fremont, CA) and CoaguChek XS Pro or XS Plus (Roche Diagnostics, Indianapolis, IN) compared with plasma INR values among warfarin treated patients. Bias and linear regression analysis were assessed for device-plasma INR comparisons. Warfarin dosing decisions were assessed for each device compared to an internal plasma INR reference method (Instrumentation Laboratories ACLTOP 500, 550, 750 analyzers (Werfen Diagnostics, Bedford MA) in one of three CLIA-certified laboratories. The thromboplastin used at our institution for INR measures is HemosIL RecombiPlasTin 2G (R2G) reagent (Werfen Diagnostics, Bedford MA) which has an International Sensitivity Index (ISI) of 1.0. Results Two hundred ninety-nine warfarin patients treated across three Mayo Clinic sites agreed to participate in the study. Common anticoagulant indications were atrial fibrillation (63.9%), venous thromboembolism (21.7%) and heart valve prosthesis (15.4%) with a 2.0–3.0 INR target range for 93.6% of patients. For the CoaguChek devices, 81.3% of values fell within 0.2 INR units of plasma INR referent and 95.3% within 0.4 units. The correlation between CoaguChek whole blood and plasma INR was excellent (R2 = 0.93). For the Coag-Sense device, 34.1% of values fell within 0.2 INR units and 60.2% within 0.4 INR units of plasma INR values, with a slightly weaker correlation between Coag-Sense whole blood and plasma INR (R2 = 0.83; P &lt; 0.0001). Mean (± standard deviation) deviation from plasma INR was 0.04 ± 0.2 for CoaguChek compared to 0.4 ± 0.3 for Coag-Sense (P &lt; 0.0001). The difference between POC devices was largely attributed to systematic negative bias between Coag-Sense and ACL TOP plasma INR values. Using the plasma INR as the reference method for dosing decision making, appropriate dosing recommendations would have occurred for 97.7% of CoaguChek and 81.6% of Coag-Sense results. Conclusion Compared to our institution's plasma reference method, INR values obtained from the CoaguChek devices (XS Pro and XS Plus) exhibited less systematic bias compared to the Coag-Sense values. This translates to greater percentage of concordant management decisions between POC and laboratory plasma INR methods when the CoaguChek device is used.
The biofilm community resurfaces: new findings and post-pandemic progress
Greenwich, Jennifer L. , Fleming, Derek , Banin, Ehud , Häußler, Susanne , Kjellerup, Birthe V. , Sauer, Karin , Visick, Karen L. , Fuqua, Clay , Fleming, Derek

Mayo Clinic

Journal of Bacteriology | September 27, 2023 | Volume: 205 | Issue: 10 | Pages: No page available

10.1128/jb.00166-23 | PMID 37756166 Get It

ABSTRACT The ninth American Society for Microbiology Conference on Biofilms was convened in-person on 13–17 November 2022 in Charlotte, NC. As the first of these conferences since prior to the start of the COVID-19 pandemic, the energy among the participants of the conference was clear, and the meeting was a tremendous success. The mixture of >330 oral and poster presentations resoundingly embodied the vitality of biofilm research across a wide range of topics and multiple scientific disciplines. Special activities, including a pre-conference symposium for early career researchers, further enhanced the attendee experience. As a general theme, the conference was deliberately structured to provide high levels of participation and engagement among early career scientists.
Fatal Infections Differentially Involve Allograft and Native Lungs in Single Lung Transplant Recipients
Cheek‐Norgan, E. Heidi, Johnson, Tucker F. , Yi, Eunhee S. , Aubry, Marie‐Christine, Pennington, Kelly M. , Roden, Anja C. , Villalba, Julian A. , Boland, Jennifer M. , Aubry, Marie-Christine, Scott, John P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 27, 2023 | Volume: 148 | Issue: 7 | Pages: 784-796

10.5858/arpa.2023-0227-oa | PMID 37756557 Get It

Context.— Respiratory infections complicate lung transplantation and increase the risk of allograft dysfunction. Allograft lungs may have different susceptibilities to infection than native lungs, potentially leading to different disease severity in lungs of single lung transplant recipients (SLTRs). Objective.— To study whether infections affect allograft and native lungs differently in SLTRs but similarly in double LTRs (DLTRs). Design.— Using an institutional database of LTRs, medical records were searched, chest computed tomography studies were systematically reviewed, and histopathologic features were recorded per lung lobe and graded semiquantitatively. A multilobar-histopathology score (MLHS) including histopathologic data from each lung and a bilateral ratio (MLHSratio) comparing histopathologies between both lungs were calculated in SLTRs and compared to DLTRs. Results.— Six SLTRs died of infection involving the lungs. All allografts showed multifocal histopathologic evidence of infection, but at least 1 lobe of the native lung was uninvolved. In 4 of 5 DLTRs, histopathologic evidence of infection was seen in all lung lobes. On computed tomography, multifocal ground-glass and/or nodular opacities were found in a bilateral distribution in all DLTRs but in only 2 of 6 SLTRs. In SLTRs, the MLHSAllograft was higher than MLHSNative (P = .02). The MLHSratio values of SLTR and DLTR were significantly different (P &lt; .001). Conclusions.— Allograft and native lungs appear to harbor different susceptibilities to infections. The results are important for the management of LTRs.